WithdrawnPHASE1, PHASE2NCT00346502
Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)
Studying Familial atypical multiple mole melanoma syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Illinois at Chicago
- Principal Investigator
- Tapas K. Das Gupta, MD, PhD, DScUniversity of Illinois at Chicago Medical Center
- Intervention
- 20% betulinic acid ointment(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2015
Study locations (1)
- University of Illinois at Chicago Medical Center, Chicago, Illinois, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00346502 on ClinicalTrials.govOther trials for Familial atypical multiple mole melanoma syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06599619Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic NeviJohn Kirkwood
- RECRUITINGNCT04095195Registry of Subjects at Risk of Pancreatic CancerAssociazione Italiana per lo Studio del Pancreas
- RECRUITINGNCT05446155BioMEL- Diagnostic and Prognostic Factors in Melanoma.Region Skane
- RECRUITINGNCT00040352Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaNational Cancer Institute (NCI)
See all trials for Familial atypical multiple mole melanoma syndrome →